

Amendment to Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of treating ~~multi-organ failure, kidney dysfunction, or wound healing, said method~~ comprising delivering a therapeutic amount of isolated mesenchymal stem cells to a patient in need thereof.
2. (Withdrawn, Currently Amended) The method of claim 1 wherein said method further comprises delivering a therapeutic amount of ~~stem cells comprise~~ hematopoietic stem cells.
3. (Canceled)
4. (Withdrawn, Currently Amended) The method of claim 1 wherein said method further comprises delivering a therapeutic amount of ~~stem cells comprise~~ hemangioblasts.
5. (Canceled)
6. (Currently Amended) The method of claim 1 wherein said isolated mesenchymal stem cells comprise non-transformed stem cells.
7. (Currently Amended) The method of claim 1 wherein said isolated mesenchymal stem cells comprise genetically modified stem cells, wherein protective potency of said cells is augmented by genetic modification prior to administration in a patient in need thereof.
8. (Currently Amended) The method of claim 1 wherein said isolated mesenchymal stem cells comprise autologous cells.
9. (Currently Amended) The method of claim 1 wherein said isolated mesenchymal stem cells comprise allogeneic cells.

10. (Currently Amended) The method of claim 1 wherein said kidney dysfunction comprises acute renal failure, acute kidney injury, early dysfunction of kidney transplant, chronic kidney disease or chronic renal failure.

11. (Withdrawn, Currently Amended) The method of claim 1 wherein said isolated mesenchymal stem cells are pre-differentiated into renal tubular cells, vascular endothelial cells or other kidney-or other organ specific cells.

12. (Withdrawn) The method of claim 4 wherein said hemangioblasts are pre-differentiated into endothelial cells.

13. (Withdrawn) The method of claim 2 wherein hematopoietic stem cells are pre-differentiated in vitro.

14. (Withdrawn) The method of claim 13 wherein said hematopoietic stem cells are pre-differentiated into endothelial cells.

15. (Withdrawn, Currently Amended) The method of claim ~~[[3]]~~1 wherein said isolated mesenchymal stem cells are pre-differentiated in vitro.

16. (Withdrawn, Currently Amended) The method of claim 15 wherein said isolated mesenchymal stem cells are pre-differentiated into endothelial cells.

17. (Withdrawn, Currently Amended) The method of claim 15 wherein said isolated mesenchymal stem cells are pre-differentiated into renal tubular cells.

18. (Withdrawn, Currently Amended) ~~[[A]]~~The method of claim 1, further comprising ~~treating multi-organ failure, kidney dysfunction, wound healing or organ dysfunction comprising~~ delivering a therapeutic amount of a stimulant of stem cell mobilization to a patient in need thereof; wherein the stimulant mobilizes stem cells to the kidneys ~~organs in need thereof~~.

19-48. (Canceled)

49. (Currently Amended) The method of claim [[45]]2 wherein a ratio of said hematopoietic stem cells to said mesenchymal stem cells is optimized for the treatment of kidney dysfunction-~~or other organ dysfunction.~~

50. (Original) The method of claim 49 wherein said stem cells are delivered to said patient in a ratio of about 0.1:1 to about 50:1 hematopoietic stem cells to mesenchymal stem cells.

51. (Currently Amended) A composition for the treatment of ~~multi-organ failure, organ kidney dysfunction, or wound healing,~~ said composition comprising an active ingredient consisting of a therapeutic amount ~~hematopoietic stem cells and~~ of mesenchymal stem cells.

52. (Original) The composition of claim 51 wherein said kidney dysfunction comprises acute renal failure, early dysfunction of kidney transplant, or chronic renal failure.

53-59. (Canceled)

60. (New) The method of claim 1, wherein between about 0.01 to about 5×10^6 mesenchymal stem cells are administered per kilogram of patient weight